Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years.~* Signed and dated written informed consent before the start of specific protocol procedures.~* ECOG PS 0-1~* Histologically/cytologically confirmed stage IV uveal melanoma~* Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria~* Any number of prior therapies (including none), with the exception of anticancer immunotherapy~Exclusion Criteria:~* Active brain metastases (symptomatic and/or requiring corticosteroids) or leptomeningeal metastases~* Previous treatment with anticancer immunotherapy~* Pregnant or nursing (lactating) women~* Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study~* Active autoimmune disease~* Immune deficiency or treatment with systemic corticosteroids~* Use of other investigational drugs (drugs not marketed for any indication) within 28 days before study drug administration~* Life expectancy of less than 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab and Entinostat (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).